Novo Nordisk gains EU approval for FlexTouch

Published: 15-Jul-2011

Danish firm\'s latest innovation within prefilled insulin pens

The European Commission has approved Novo Nordisk’s new FlexTouch prefilled insulin pen. Approval has been granted for both NovoRapid (insulin aspart) and Levemir (insulin detemir), both modern insulins that are currently delivered in the FlexPen delivery device.

The Danish pharmaceutical firm says FlexTouch, its latest prefilled delivery system, offers a new insulin injection experience for users. Current insulin pens require users to inject their insulin using the force of their thumb to push the button. For some patients this can be difficult. FlexTouch has an easy touch button, which requires very little force to inject the insulin at any dose.

FlexTouch contains 300 units of insulin and doses in one-unit increments, from 1–80 units. It is compatible with NovoTwist needles, which are supplied in 5mm (32G Tip) and 8mm (30G) versions. An audible and tactile ‘click’ confirms attachment of the needle.

The launch of the FlexTouch in the EU is dependent on negotiations in individual countries.

You may also like